S

SELLAS Life Sciences Group
D

SLS

14.150
USD
1.68
(13.55%)
قبل الجلسة·13.325USD-0.825(-5.83%)
حجم التداول
279,818
الربح لكل سهم
-0
العائد الربحي
-
P/E
-61
حجم السوق
2,811,845,808
أصول ذات صلة المقالات
المزيد

العنوان: SELLAS Life Sciences Group

القطاع: Healthcare
الصناعة: Biotechnology
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.